American Society of Clinical Oncology Annual Meeting
ASCO 2025
- AbbVie Features New Data Across Solid Tumors and Blood Cancers
- Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559
- Actuate Therapeutics Presents Topline Elraglusib Ph 2 Data: Trial Meets Primary Endpoint of mOS and Doubles 1-Year Survival in 1L Metastatic Pancreatic Cancer
- Adagene Announces Updated Data from Ph 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA in CRC
- Affimed N.V. announced abstract on Ph 2 LuminICE-203 study of acimtamig + AlloNK® (AB-101) and two abstracts on AFM24 + atezolizumab in NSCLC
- Alligator Bioscience Presents OPTIMIZE-1 Biomarker Data
- Allogene Therapeutics Provides Updated Ph 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced RCC
- Antengene to Present Clinical Results from 2 Studies in CPI-resistant Solid Tumors
- Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Trial
- Arvinas and Pfizer’s Vepdegestrant Significantly Improves PFS for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- Ascentage Pharma Announces Clinical Data of Lisaftoclax in Venetoclax-Refractory Patients
- Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term OS in Metastatic HSPC
- Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression
- Bantam Pharmaceutical to Present poster to ongoing Ph 1 trial of BTM-3566 in patients with R/R mature B-cell lymphomas
- BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in 1L CLL
- Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Ph 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC
- Bicycle Therapeutics Announces Poster Presentations
- BioAtla Presents Ph 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Antitumor Activity in HPV+ OPSCC at the 1.8 mg/kg Q2W dosing regimen
- BioLineRx Announces New Pilot Phase Data from Ph 2 Combination Trial of Motixafortide in 1L Pancreatic Cancer (PDAC)
- Breakthrough Clinical Data for LBL-024 in 1L Treatment of Advanced EP-NEC
- BriaCell Reports Robust Overall Survival and Clinical Benefit Data
- Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced ESR1 mutant HR+ve breast cancer in SERENA-6 Ph 3 trial
- Candel Therapeutics Presents Positive Ph 3 CAN-2409 Results in Localized Prostate Cancer
- Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in mTNBC
- CARsgen Presents Research Results on Satri-cel
- CCM Biosciences announces the presentation of next-gen FLT3 inhibitor drug program for AML
- CERo Therapeutics to Present Poster on CER-1236
- Corcept Presents Pivotal Clinical Data: Relacorilant Improves PFS & OS in Patients with Platinum-Resistant Ovarian Cancer
- Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Ph 2b REZILIENT1 Trial of Zipalertinib
- DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced NSCLC
- Debiopharm presents three poster presentations on Debio 0123 in multiple solid tumor indications
- Lilly presents first clinical data for FRα targeting ADC in platinum-resistant ovarian cancer
- Eisai to present clinical research across its oncology portfolio and pipeline
- Enhertu + pertuzumab reduced the risk of disease progression or death by 44% vs. THP in 1L HER2+ve metastatic breast cancer patients in DESTINY-Breast09 Ph 3 trial
- ENHERTU Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a 2L Therapy in Patients with HER2+ve Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Ph 3 Trial
- Exelixis Announces Results from Ph 1b/2 STELLAR-002 Trial of Zanzalintinib + Immune Checkpoint Inhibitors in Advanced Kidney Cancer
- FORE Biotherapeutics Presented Plixorafenib Abstract
- Foundation Medicine Presented Over 15 Abstracts
- Genentech’s Tecentriq Combined With Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage SCLC
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Ph 1/2 RAINFOL™-01 Trial
- GV20 Therapeutics Presents Updated Ph 1 Monotherapy Data on GV20-0251
- HUTCHMED Highlights SACHI Ph 3 Study Data
- ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy
- Imdelltra significantly reduced risk of death by 40% in SCLC patients
- Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Ph 3 trial
- Immatics IMA203 PRAME Cell Therapy Data Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
- ImmuneOncia Announces Interim Results from Ph 1b Trial of IMC-002
- ImPact Biotech Announces Late-Breaking Podium Presentation Highlighting ENLIGHTED Padeliporfin VTP Study Interim Analysis
- IMUNON Announces Oral Presentation Highlighting Survival Data from Ph 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
- Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
- Innovent Biologics Announces Updated Data of IBI363 from Ph 1 and 2 Studies on Immunotherapy-treated Advanced Malignant Melanoma
- Innovent Biologics Announces Updated Date of IBI363 from Ph 1 Studies in Advanced CRC
- InxMed Announces Ph 1b/2 Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors
- Iovance Announces 5-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma
- Kite Presents New Real-World Data Supporting Use of Yescarta® in Outpatient Care Setting for Patients with R/R LBCL
- Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib
- Late-breaking analysis demonstrates characteristics associated with long-term OSl with Onivyde® regimen in metastatic pancreatic adenocarcinoma
- Libtayo® (cemiplimab) Ph 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk CSCC
- Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for R/R MM
- Menarini Group Presents Updated Data of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)
- Merck Announces MK-1084 Shows Antitumor Activity in Ph 1 Trial of Patients With Advanced CRC and NSCLC With KRAS G12C Mutations
- Merck’s Zilovertamab Vedotin at 1.75 mg/kg Dose + SOC Showed Promising Antitumor Activity, Including CR, in R/R DLBCL in Ph 2 Portion of waveLINE-003 Trial
- Mersana Therapeutics Reports Additional Positive Interim Ph 1 Data for Emi-Le
- Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
- Mythic Therapeutics Presents Compelling Efficacy Data from Ph 1 KisMET-01 Study of MYTX-011 in NSCLC
- New data show Roche’s Itovebi significantly extended survival in PIK3CA-mutated HR+ve, HER2neg advanced breast cancer
- New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the Ph 2 TUXEDO-3 study
- Novita Pharmaceuticals Announces Oral Presentation of Ph 2 NP-G2-044 Data
- Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
- Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC
- Nuvalent Presented Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330
- Nuvation Bio Presented New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive NSCLC
- Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study
- Oncolytics Biotech® to Present New Clinical Trial Data Showing Pelareorep’s Immune Activation Capabilities
- OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and NSCLC
- PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers
- Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant mCRC
- Rakuten Medical Announces Trial in Progress Poster Presentation and Enrollment Expansion to Taiwan for Global Ph 3 ASP-1929-381
- Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful PFS
- Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
- Results From the Ph 3 PANOVA-3 Trial of Novocure’s TTFields Therapy for Pancreatic Cancer Presented
- Rigel Announces Poster Presentations from the GAVRETO® (pralsetinib) Ph 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors and supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML
- Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage SCLC
- Sapience Therapeutics Provides Data Update from Ph 2 Trial of Lucicebtide in GBM Patients
- Servier announces Presentations in IDH-Mutated Cancers
- Strand Therapeutics Announces Initial First-in-human Ph 1 Data for STX-001 in Patients with Advanced Solid Tumors
- Syncromune Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Ph 1 Metastatic Prostate Cancer Trial
- Transgene and NEC Present Durable DFS and Sustained T Cell Responses at 24 Months with TG4050
- Trodelvy + Keytruda Reduces Risk of Disease Progression or Death by 35% Vs Keytruda and Chemo in 1L PD-L1+ Metastatic TNBC
- Verastem Oncology Announces Updated Data from Ph 1 Study in China of GFH375 (VS-7375)
- Verismo Therapeutics presented overview of ongoing STAR-101 Ph 1 clinical study
- Volastra Announces Initial Data from First-in-Human Ph 1/2 Trial of VLS-1488
- Xilio Therapeutics Announces Updated Ph 2 Data for Vilastobart + Atezolizumab in Patients with Metastatic MSS CRC
- Zai Lab Presents Positive Ph 1 Data for ZL-1310 Demonstrating Anti-Tumor Activity and Safety in Patients with Extensive-Stage SCLC
- Zentalis Pharmaceuticals presents Ph 1/2 trial of azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant CRC
- Zymeworks Inc. announced multiple presentations related to oncology programs